The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19
Open accessAbstract
Importance: Coronavirus disease 2019 (COVID-19) has infected more than 8.1 million US residents and killed more than 221 000. There is a dearth of research on epidemiology and clinical outcomes in US patients with COVID-19. Objectives: To characterize patients with COVID-19 treated in US hospitals and to examine risk factors associated with in-hospital mortality. Design, Setting, and Participants: This cohort study was conducted using Premier Healthcare Database, a large geographically diverse all-payer hospital administrative database including 592 acute care hospitals in the United States. Inpatient and hospital-based outpatient visits with a principal or secondary discharge diagnosis of COVID-19 (International Classification of Diseases, Tenth Revision, Clinical Modification diagnosis code, U07.1) between April 1 and May 31, 2020, were included. Exposures: Characteristics of patients were reported by inpatient/outpatient and survival status. Risk factors associated with death examined included patient characteristics, acute complications, comorbidities, and medications. Main Outcomes and Measures: In-hospital mortality, intensive care unit (ICU) admission, use of invasive mechanical ventilation, total hospital length of stay (LOS), ICU LOS, acute complications, and treatment patterns. Results: Overall, 64 781 patients with COVID-19 (29 479 [45.5%] outpatients; 35 302 [54.5%] inpatients) were analyzed. The median (interquartile range [IQR]) age was 46 (33-59) years for outpatients and 65 (52-77) years for inpatients; 31 968 (49.3%) were men, 25 841 (39.9%) were White US residents, and 14 340 (22.1%) were Black US residents. In-hospital mortality was 20.3% among inpatients (7164 patients). A total of 5625 inpatients (15.9%) received invasive mechanical ventilation, and 6849 (19.4%) were admitted to the ICU. Median (IQR) inpatient LOS was 6 (3-10) days. Median (IQR) ICU LOS was 5 (2-10) days. Common acute complications among inpatients included acute respiratory failure (19 706 [55.8%]), acute kidney failure (11 971 [33.9%]), and sepsis (11 910 [33.7%]). Older age was the risk factor most strongly associated with death (eg, age ≥80 years vs 18-34 years: odds ratio [OR], 16.20; 95% CI, 11.58-22.67; P < .001). Receipt of statins (OR, 0.60; 95% CI, 0.56-0.65; P < .001), angiotensin-converting enzyme inhibitors (OR, 0.53; 95% CI, 0.46-0.60; P < .001), and calcium channel blockers (OR, 0.73; 95% CI, 0.68-0.79; P < .001) was associated with decreased odds of death. Compared with patients with no hydroxychloroquine or azithromycin, patients with both azithromycin and hydroxychloroquine had increased odds of death (OR, 1.21; 95% CI, 1.11-1.31; P < .001). Conclusions and Relevance: In this cohort study of patients with COVID-19 infection in US acute care hospitals, COVID-19 was associated with high ICU admission and in-hospital mortality rates. Use of statins, angiotensin-converting enzyme inhibitors, and calcium channel blockers were associated with decreased odds of death. Understanding the potential benefits of unproven treatments will require future randomized trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
First case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030
CDC COVID-19 Response Team, CDC COVID-19 Response Team, Bialek, S., Boundy, E., Bowen, V., Chow, N., Cohn, A., Dowling, N., Ellington, S., Gierke, R., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6912e2 · Cited by 2,277
Hospitalization and mortality among Black patients and White patients with Covid-19.
Price-Haywood, E. G., Burton, J., Fort, D., & Seoane, L. (2020) · New England Journal of Medicine · doi:10.1056/nejmsa2011686 · Cited by 1,660
Guzik, T. J., Mohiddin, S. A., Dimarco, A., Patel, V., Savvatis, K., Marelli-Berg, F. M., Madhur, M. S., Tomaszewski, M., Maffia, P., D’Acquisto, F., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa106 · Cited by 1,440
CDC COVID-19 Response Team, CDC COVID-19 Response Team, Chow, N., Fleming-Dutra, K., Gierke, R., Hall, A., Hughes, M., Pilishvili, T., Ritchey, M., Roguski, K., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6913e2 · Cited by 1,404
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Boulware, D. R., Pullen, M. F., Bangdiwala, A. S., Pastick, K. A., Lofgren, S. M., Okafor, E. C., Skipper, C. P., Nascene, A. A., Nicol, M. R., Abassi, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2016638 · Cited by 1,318
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022926 · Cited by 1,265
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
Cavalcanti, A. B., Zampieri, F. G., Rosa, R. G., Azevedo, L. C. P., Veiga, V. C., Avezum, A., Damiani, L. P., Marcadenti, A., Kawano-Dourado, L., Lisboa, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2019014 · Cited by 1,083
The epidemiology, diagnosis and treatment of COVID-19
Zhai, P., Ding, Y., Wu, X., Long, J., Zhong, Y., & Li, Y. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105955 · Cited by 1,014
Arshad, S., Kilgore, P., Chaudhry, Z. S., Jacobsen, G., Wang, D. D., Huitsing, K., Brar, I., Alangaden, G. J., Ramesh, M. S., McKinnon, J. E., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.06.099 · Cited by 546
Rentsch, C. T., Kidwai-Khan, F., Tate, J. P., Park, L. S., King, J. T., Skanderson, M., Hauser, R. G., Schultze, A., Jarvis, C. I., Holodniy, M., et al. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003379 · Cited by 526
Singh, A. K., Singh, A., Shaikh, A., Singh, R., & Misra, A. (2020) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2020.03.011 · Cited by 488
Aggarwal, S., Garcia-Telles, N., Aggarwal, G., Lavie, C., Lippi, G., & Henry, B. M. (2020) · Diagnosis · doi:10.1515/dx-2020-0046 · Cited by 377
Imam, Z., Odish, F., Gill, I., O’Connor, D., Armstrong, J., Vanood, A., Ibironke, O., Hanna, A., Ranski, A., & Halalau, A. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13119 · Cited by 369
Hyperglycemia, hydroxychloroquine, and the COVID‐19 pandemic
Brufsky, A. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25887 · Cited by 207
Potential therapeutic agents against COVID-19: What we know so far
Lu, C.-C., Chen, M.-Y., Lee, W.-S., & Chang, Y.-L. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000318 · Cited by 196
Piva, S., Filippini, M., Turla, F., Cattaneo, S., Margola, A., De Fulviis, S., Nardiello, I., Beretta, A., Ferrari, L., Trotta, R., et al. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.04.004 · Cited by 171
COVID-19: Therapeutics and Their Toxicities
Chary, M. A., Barbuto, A. F., Izadmehr, S., Hayes, B. D., & Burns, M. M. (2020) · Journal of Medical Toxicology · doi:10.1007/s13181-020-00777-5 · Cited by 122
Epidemiological and initial clinical characteristics of patients with family aggregation of COVID-19
Xia, X.-Y., Wu, J., Liu, H.-L., Xia, H., Jia, B., & Huang, W. (2020) · Journal of Clinical Virology · doi:10.1016/j.jcv.2020.104360 · Cited by 92
As COVID-19 cases, deaths and fatality rates surge in Italy, underlying causes require investigation
Rubino, S., Kelvin, N., Bermejo-Martín, J. F., et al. (2020) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.12734 · Cited by 90
Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic
Scuccimarri, R., Sutton, E. D., & Fitzcharles, M. (2020) · The Journal of Rheumatology · doi:10.3899/jrheum.200369 · Cited by 27
Cited by
Kompaniyets, L., Pennington, A. F., Goodman, A. B., Rosenblum, H. G., Belay, B., Ko, J. Y., Chevinsky, J. R., Schieber, L. Z., Summers, A. D., Lavery, A. M., et al. (2021) · Preventing Chronic Disease · doi:10.5888/pcd18.210123 · Cited by 372
Mude, W., Oguoma, V. M., Nyanhanda, T., Mwanri, L., & Njue, C. (2021) · Journal of Global Health · doi:10.7189/jogh.11.05015 · Cited by 262
Vinayagamoorthy, K., Pentapati, K. C., & Prakash, H. (2022) · Mycoses · doi:10.1111/myc.13447 · Cited by 53
Metadata
- Authors
- Rosenthal, N., Cao, Z., Gundrum, J., Sianis, J., & Safo, S.
- Venue
- JAMA Network Open
- Publisher
- American Medical Association (AMA)
- Published
- 2020-12-10
- Volume
- 3
- Issue
- 12
- Pages
- e2029058
- ISSN
- 2574-3805 (ISSN-L)
- OpenAlex
- W3112500788
- Cited by
- 484
- References
- 24
- FWCI
- 11.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.